Home » News » Page 32

READ MORE

COMMUNICATION MAKES COMMUNITY

MEDIA CENTER

Read Gornitzky & Co.'s latest news.

Gornitzky is representing A.Y. Yam-Kinneret in an administrative petition that was filed against the Mayor of Tiberias, the city engineer and the Municipality with a request to receive the building permit for a luxurious residential project “Agam” on the shores of the Sea of Galilee.

Australia and Israel Enter into a Tax Treaty.

Gornitzky represented real estate companies controlled by Tshuva Group in an administrative petition that was filed against the Tel Aviv Municipality.

Gornitzky represented a regional marketing agent of Mifal Hapayis in a claim that was filed against it and against Mifal Hapayis, by a bidder who had lost in a tender.

Gornitzky represented Kaldash Construction Ltd. in an appeal that was filed with the Supreme Court by the Municipality of Jerusalem, against the judgment that had been handed down by the Jerusalem District Court.

Completion of the financing for the acquisition of the share interest of the Ofer Group in Mizrahi Bank by L.Y.N (Holdings) Ltd.

Completion of the Separation Transaction between Ofer Group’s “Real Holdings” and “Financial Holdings”.

Gornitzky represented Melisron Ltd. in its NIS 220 million public offering of bonds on the TASE.

Gornitzky represented Israel Ports Development & Assets Company Ltd., in the issuance of commercial securities in a total scope of NIS 400 million

Gornitzky Represents Warburg Pincus Fund in the Precedential Acquisition of Leumi Card.

Gornitzky is representing the public biomedical company, Bonus BioGroup Ltd., in a motion to modify the terms of option warrants.

Gornitzky is representing Zero Waste Ltd. in a petition that was filed against the company winning of the BOT tender.

Gornitzky represented Rapyd Financial Network (2016) Ltd., in a $40 million financing round.

Gornitzky represented the underwriters, led by Oppenheimer & Co., in the USD 15.4 million follow-on offering of BioLineRx Ltd.

Gornitzky represented the underwriters, led by Goldman Sachs, J.P. Morgan and Jefferies, in the USD 172.5 million follow-on offering of UroGen Pharma Ltd.